SCHEMBL29665101

SCHEMBL29665101

O=C1NC(=S)S/C1=C\c1ccc(-c2cc(C(=O)O)ccc2Cl)o1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.82
POLB P06746 1/20 0.82
KMT2A Q03164 1/20 0.82
TDP1 Q9NUW8 1/20 0.82
L3MBTL1 Q9Y468 1/20 0.82
INSR P06213 2/20 0.69
IGF1R P08069 2/20 0.69
PIK3CG P48736 5/20 0.67
PIK3CA P42336 2/20 0.64
PTP4A3 O75365 1/20 0.64
STAT3 P40763 1/20 0.57
SLC1A3 P43003 3/20 0.56
HSPD1 P10809 1/20 0.56
HSPE1 P61604 1/20 0.56
TTR P02766 1/20 0.55
ITGB2 P05107 1/20 0.54
ITGAM P11215 1/20 0.54
MYC P01106 1/20 0.54
IL1RN P18510 1/20 0.54
ERAP1 Q9NZ08 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12812715 1.00 MEN1 (0.82) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3362325 1.00 MEN1 (0.82) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3362327 1.00 MEN1 (0.82) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL30657757 0.87 INSR (0.69) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL13236142 0.85 IGF1R (0.74) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3890812 0.85 IGF1R (0.74) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3890807 0.85 IGF1R (0.74) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL12812667 0.85 INSR (0.69) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL12990164 0.82 MEN1 (0.58) MEN1POLBKMT2ATDP1L3MBTL1
SCHEMBL3363029 0.82 MEN1 (0.58) MEN1POLBKMT2ATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250312367-A1 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF ADARX PHARMACEUTICALS, INC. (US) 2025-10-09 US disclosed
EP-4522628-A2 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF Adarx Pharmaceuticals, Inc. (US) 2025-03-19 EP disclosed
WO-2023220737-A2 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF ADARX PHARMACEUTICALS, INC. (US) 2023-11-16 WO disclosed
CN-110272388-B 4-dithioformic acid piperazine-3-nitro-1, 8-naphthalimide derivative and synthesis method and application thereof 桂林医学院 2022-06-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312367-A1 OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF POLRMT, TARDBP, NSUN2 MEN1 1631/4885POLB 20/4885KMT2A 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.